WWE Clash of Champions 2017: 3 Possible Upsets on the Horizon
KISS musician denies sexual battery claims
Trumps thanks Putin for lauding strong economic progress' in US
Alyssa Milano slams Matt Damon's remark on sexual abuse
Prince Harry interviews Obama
Price Target Estimates for Flexion Therapeutics, Inc. (FLXN)
11 October 2017, 03:48 | Myron Mathis
Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company's stock valued at $1,131,000 after purchasing an additional 338 shares during the last quarter. BMO Capital Markets' target price indicates a potential upside of 23.62% from the company's previous close. Zacks Investment Research cut Flexion Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, July 13th.
President and CEO, Clayman Michael D., purchased 5,000 common shares of Flexion Therapeutics, Inc. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Of those analysts, 4 rate stock as a Strong Buy, 0 rate it as Hold, and just no analyst rates it as a Moderate Sell. They may also be used to assist the trader figure out proper support and resistance levels for the stock.
Analysts expect Flexion Therapeutics Inc (NASDAQ:FLXN) to report $-0.95 EPS on November, 6.They anticipate $0.30 EPS change or 46.15% from last quarter's $-0.65 EPS. The relative volume of the stock is 12.94, while its market cap is $952.55 Million.
The most recent open market insider trade was Buy of 1,000 shares on a day where the closing price was 24.2.
Flexion Therapeutics has a 52 week low of $15.93 and a 52 week high of $32.25 FLXN's total market value is presently $0.
Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings data on Tuesday, August 8th.
Among 3 analysts covering AMN Healthcare (NYSE:AMN), 2 have Buy rating, 0 Sell and 1 Hold. Comparatively, Flexion Therapeutics, Inc. posted earnings of $-0.82 per share in the same quarter past year. "(FLXN)" was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this article on another publication, it was illegally copied and republished in violation of global copyright and trademark law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/10/09/flexion-therapeutics-inc-flxn-pt-raised-to-37-00-at-bmo-capital-markets.html.
12/22/2016 - Raymond James began new coverage on Flexion Therapeutics Inc giving the company a "strong buy" rating. Over the last three months, insiders purchased 5,375 shares of company stock valued at $131,575. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company's stock valued at $441,000 after purchasing an additional 811 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: "Janney Montgomery Scott Boosts Flexion Therapeutics, Inc". Janney Montgomery Scott LLC now owns 17,970 shares of the specialty pharmaceutical company's stock valued at $363,000 after acquiring an additional 4,395 shares during the period. Guggenheim Capital LLC acquired a new stake in Flexion Therapeutics during the fourth quarter worth $1,326,000. Short interest grew 367,303 over that period. Unusual volume shows something has likely happened in the stock-such as a news release or traders have become anxious or euphoric about the stock's potential. Finally, The Manufacturers Life Insurance Company raised its position in Flexion Therapeutics by 3.9% during the second quarter.
Analysts' ultimate objective when projecting revenue is to determine the appropriate value for a stock. Company insiders own 15.98% of the company's stock.
Looking further out, over the past twelve months, Flexion Therapeutics, Inc.'s stock was 41.27% and 27.44% over the last quarter and 6.09% for the past six months. The Firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis.
Reviewing the Insider Trends for Ford Motor Company (F)
David Einhorn increased its stake in General Mtrs Co (GM) by 204.19% based on its latest 2017Q2 regulatory filing with the SEC. Commonwealth Comml Bank Of reported 1.18M shares. (NASDAQ:MAR) has been 2.15 million shares per day over the past 30 days.
Donald Trump is acting like a fifth-grade bully
And if the American body politic doesn't experience a complete meltdown this week, perhaps others will notice. On Oct. 10, Trump took to social media to blast an interview that Corker had given to The New York Times .
General Electric board shake-up continues
GE needs to implement massive changes to its current operating structure in order to turn around its current negative performance. Finally, Catawba Capital Management VA raised its position in General Electric Company by 5.9% in the first quarter.
Thai junta chief vows elections in November 2018
He said the election date will be announced in June, with the actual voting taking place in November, local media reported. The changes are expected to weaken the country's biggest party, Puea Thai, which has won every election since 2001.
11-year-old Utah girl learns her adoption is final
A video of an 11-year-old girl's reaction to learning she will be adopted by her foster family went viral, according to KUTV-TV . Alexander thought the moment was so attractive that she got Fisher's permission and shared the video on social media.
NLDS Game 4 Preview: Nationals vs Cubs
How, just when he was ready to return, he got sick, and how he had barely a week to try to get his timing back. "Lots of family. But that first surrendered hit, a double by Ben Zobrist , was enough to get him the hook from Nationals manager Dusty Baker .